The Effect of Food on Tramadol and Celecoxib Bioavailability Following Oral Administration of Co-Crystal of Tramadol–Celecoxib (CTC): A Randomised, Open-Label, Single-Dose, Crossover Study in Healthy Volunteers

• Published in: Clinical drug investigation Vol. 38; no. 9; pp. 819 - 827
• Main Authors: Encina, Gregorio, Encabo, Mercedes, Escriche, Marisol, Lahjou, Mounia, Sicard, Eric, Smith, Kevin, Gascon, Neus, Plata-Salamán, Carlos, Videla, Sebastián
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2018; Springer Nature B.V
• Subjects: Adolescent; Adult; Analgesics; Analgesics, Opioid - adverse effects; Analgesics, Opioid - blood; Analgesics, Opioid - pharmacokinetics; Area Under Curve; Arthritis; Bioavailability; Biological Availability; Celecoxib - adverse effects; Celecoxib - blood; Celecoxib - pharmacokinetics; Clinical trials; Cross-Over Studies; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - blood; Cyclooxygenase 2 Inhibitors - pharmacokinetics; Drug Combinations; Drug dosages; Fasting - metabolism; Female; Food; Food-Drug Interactions; Healthy Volunteers; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Narcotics; Original; Original Research Article; Pain; Pharmaceuticals; Pharmacology/Toxicology; Pharmacotherapy; Studies; Tramadol - adverse effects; Tramadol - analogs & derivatives; Tramadol - blood; Tramadol - pharmacokinetics; Young Adult
• DOI: 10.1007/s40261-018-0672-y
• ISSN: 1173-2563; 1179-1918

Background and Objective Co-Crystal of Tramadol–Celecoxib (CTC), in development for the treatment of moderate to severe acute pain, is a first-in-class co-crystal containing a 1:1 molecular ratio of two active pharmaceutical ingredients; rac-tramadol·HCl and celecoxib. This randomised, open-label, crossover study compared the bioavailability of both components after CTC administration under fed and fasting conditions. Methods Healthy adults received single doses of 200 mg CTC under both fed and fasting conditions (separated by a 7-day washout). Each dose of CTC was administered orally as two 100 mg tablets, each containing 44 mg tramadol·HCl and 56 mg celecoxib. In the fed condition, a high-fat, high-calorie meal [in line with recommendations by the US Food and Drug Administration (FDA)] was served 30 min before CTC administration. Tramadol, O -desmethyltramadol and celecoxib plasma concentrations were measured pre- and post-dose up to 48 h. Pharmacokinetic parameters were calculated using non-compartmental analysis. Safety was also assessed. Results Thirty-six subjects (18 female/18 male) received one or both doses of CTC; 33 provided evaluable pharmacokinetic data under fed and fasting conditions. For tramadol and O -desmethyltramadol, fed-to-fasting ratios of geometric least-squares means and corresponding 90% confidence interval (CI) values for maximum plasma concentration ( C max ) and extrapolated area under the plasma concentration–time curve to infinity (AUC ∞ ) were within the pre-defined range for comparative bioavailability (80–125%). For celecoxib, C max and AUC ∞ fed-to-fasting ratios (90% CIs) were outside this range, at 130.91% (116.98–146.49) and 129.34% (121.78–137.38), respectively. The safety profile of CTC was similar in fed and fasting conditions. Conclusions As reported for standard-formulation celecoxib, food increased the bioavailability of celecoxib from single-dose CTC. Food had no effect on tramadol or O -desmethyltramadol bioavailability. Clinical trial registration number 152052 (registered with the Therapeutic Products Directorate of Health Canada)